Experience

Idogen AB

• Sweden
• Biotechnology Research
• 1 - 100 Employee

• Senior Scientist

  • Aug 2018 - Present

  • Continuously involved in the innovation stream for conceptualising novel ideas to refine the Idogen product.Designed, established and optimised:• immunoassays to assess phenotypic and functional characteristics of the Idogen (ItolDC) cell product. • cell and molecular assays to define MoA for the ItolDC• assays to assess antigen loading and antigen-specific suppression of the Idogen cell product.• protocols for the upscaling and manufacturing process of the ItolDC product



Lund University

• Sweden
• Higher Education
• 700 & Above Employee

• Post-Doctoral Scientist

  • Feb 2017 - Aug 2018

  Investigating the regulatory pathways in NK cell differentiation from hematopoietic stem cells.Sitnicka LabThe overall aim of this project is to identify the key pathways driving NK cell development and apply them for NK cell expansion. The other important goal is to uncover mechanisms underlying NK cell disorders: the impact of disrupted regulatory signaling and malignant transformation on NK cell generation and function, and how NK cell impairment contributes to leukemia onset and progression. The project will extend our understanding the mechanisms controlling NK cells in normal and malignant hematopoiesis and will provide basis for the improvement of NK-cell based immunotherapy.



Wyss Translational Center Zurich

• Wissenschaftler Mitarbeiter

  • Dec 2015 - Jan 2017

  Establishing Tolerance in Multiple Sclerosis (ETIMSred Clinical Trial) Pre-Clinical Study (Phase 1b trial; Toxicity, Efficacy, Biodistribution).• Optimised assays to track changes in patients with Multiple Sclerosis following treatment with the ETIMS product. • Designed and refined multifluorophore panels to immunophenotype cells of interest in the peripheral blood compartment as well as the CSF as part of the immune monitoring process.• Participated in the design and execution of protocols for the in vivo toxicology, cell tracking (IVIS) studies as well as using the EAE model to assess the safety and efficacy of the ETIMS cell therapy.• Established calcium flux and other apoptotic assays to investigate the effect of peptide coupling on erythrocytes.• Continuously involved in analysing, interpreting, presenting and reporting research findings at both internal meetings and external scientific NIMS seminars.



The Institute of Virology and Immunology (IVI)

• Post-Doctoral Scientist

  • Feb 2013 - Dec 2015

  A “universal” Influenza Vaccine through Synthetic, Dendritic Cell-Targeted Self-Replicating RNA Vaccines.McCullough Lab.The core aim of the UNIVAX consortium was to examine the interactions of Dendritic Cells with self-amplifying RNA (RepRNA) from the non-cytopathogenic Classical Swine Fever Virus (CFSV), promoting replication and translation. A number of cationic lipids were assessed for delivery and facilitating RepRNA translation. Using both in vitro and in vivo studies these investigations characterize the lipid-mediated binding and delivery of RepRNA to DC populations, leading to translation of the encoded influenza virus antigens of interest. In addition, several assays were developed to assess the proliferation and functional phenotype of antigen-specific proliferation following the vaccination with the various lipoplexes.